Mesenchymal stem cells differentiated into chondrocyte—Like cells

Narakornsak, Suteera; Poovachiranon, Naree; Peerapapong, Lamaiporn; Pothacharoen, Peraphan; Aungsuchawan, Sirinda

doi:10.1016/j.acthis.2016.04.004

Cited by 18 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated that, the growth curve of the proliferation assay recorded in the previous study showed a similar pattern to the MSCs growth pattern, which indicated a short lag-phase at the early stage of proliferation. The log-phase was initiated until reaching the highest peak and then plateaued for a couple of days afterward [ 21 , 23 , 24 , 54 , 55 ].…”

Section: Discussionmentioning

confidence: 99%

“…The hAF-MSCs obtained from the second-trimester of a pregnancy possess a self-renewal capacity and multilineage differentiation potential [ 18 , 19 , 20 ]. They can differentiate into chondrocytes [ 21 , 22 ], endothelial cells [ 23 ], osteocytes [ 24 ] and cardiomyocytes [ 25 ]. Furthermore, they have been shown to be effective in the treatment of many diseases such as MI [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differentiation of cardiomyocyte-like cells from human amniotic fluid mesenchymal stem cells by combined induction with human platelet lysate and 5-azacytidine

Markmee

Aungsuchawan

Tancharoen

et al. 2020

Heliyon

Self Cite

View full text Add to dashboard Cite

Human amniotic fluid mesenchymal stem cells (hAF-MSCs) have been shown to be effective in the treatment of many diseases. Platelet lysate (PL) contains multiple growth and differentiation factors; therefore, it can be used as a differentiation inducer. In this study, we attempted to evaluate the efficiency of human platelet lysate (hPL) on cell viability and the effects on cardiomyogenic differentiation of hAF-MSCs. When treating the cells with hPL, the result showed an increase in cell viability. Expressions of cardiomyogenic specific genes, including GATA4 , cTnT , Cx43 and Nkx2.5 , were higher in the combined treatment groups of 5-azacytidine (5-aza) and hPL than the expressions of cardiomyogenic specific genes in the control group and in the 5-aza treatment group. In terms of the results of immunofluorescence and immunoenzymatic staining, the highest expressions of cardiomyogenic specific proteins were revealed in combined treatment groups. It can be summarized that hPL may be an effective supporting cardiomyogenic supplementary factor for cardiomyogenic differentiation in hAF-MSCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Differentiation of cardiomyocyte-like cells from human amniotic fluid mesenchymal stem cells by combined induction with human platelet lysate and 5-azacytidine

Markmee

Aungsuchawan

Tancharoen

et al. 2020

Heliyon

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to the properties of MSCs, they are able to differentiate according to their mesodermal lineage. Previous studies have shown the potential of hAF-MSCs to be differentiated into osteocytes and chondrocytes (27,28). In this present study, hAF-MSCs that were induced using VEGF when cultured with hPL-supplemented media were capable of endothelial differentiation.…”

Section: Discussionmentioning

confidence: 99%

Human platelet lysate as an alternative to fetal bovine serum for culture and endothelial differentiation of human amniotic fluid mesenchymal stem cells

et al. 2019

Self Cite

View full text Add to dashboard Cite

Human amniotic fluid (hAF) mesenchymal stem cells (MSCs) are commonly cultured in medium containing FBS. However, there are concerns about using animal serum in therapeutic applications due to the potential for immunogenic reactions and the risk of transmission of pathogens. For safety reasons, human platelet lysate (hPL) has been suggested as a replacement for FBS because it appears to be a natural source of growth factors. In this present study, it was investigated whether FBS could be substituted with hPL in hAF-MSCs culture without affecting their properties. Pooled hPL was generated by the freeze-thaw method. The concentration of hPL was selected after evaluation by MTT assay. The hAF-MSCs were cultured in FBS- or hPL-supplemented conditions and shared a fibroblast-like morphology. Cell proliferation assays showed that the growth characteristic of hAF-MSCs cultured in 10% hPL-supplemented media was similar to those cultured in 10% FBS-supplemented media. The expression of MSC markers did not differ between the cells cultured in the different conditions. The endothelial differentiation potential was also investigated. Reverse transcription-quantitative (RT-q)PCR revealed that induced cells supplemented with hPL showed an increase level of endothelial specific gene expression compared to the FBS-supplemented cells. Immunofluorescence analysis showed specific protein localization in both induced cell groups. Additionally, induced cells supplemented with hPL had the potential to form networks on Matrigel. This present study indicated that hPL could be used to culture and enhance the endothelial differentiation potential of hAF-MSCs.

show abstract

“…To overcome this hurdle, a better understanding of the primitive cell population in umbilical cord blood is imperative for optimizing cell expansion. Furthermore, although the differentiation capacity of cord blood MNCs has been extensively studied [18–20], little is known about whether MNCs have the pluripotent capacity to differentiate into MSCs or OECs or are a mixture of progenitor cells with determined MSC or OEC fates.…”

Section: Discussionmentioning

confidence: 99%

Human Cord Blood‐Derived CD133⁺/C‐Kit⁺/Lin⁻ Cells Have Bipotential Ability to Differentiate into Mesenchymal Stem Cells and Outgrowth Endothelial Cells

Cárdenas

Kwon

Maeng

2016

Stem Cells International

View full text Add to dashboard Cite

Recent evidence suggests that mononuclear cells (MNCs) derived from bone marrow and cord blood can differentiate into mesenchymal stem cells (MSCs) or outgrowth endothelial cells (OECs). However, controversy exists as to whether MNCs have the pluripotent capacity to differentiate into MSCs or OECs or are a mixture of cell lineage-determined progenitors of MSCs or OECs. Here, using CD133+/C-kit+/Lin− mononuclear cells (CKL− cells) isolated from human umbilical cord blood using magnetic cell sorting, we characterized the potency of MNC differentiation. We first found that CKL− cells cultured with conditioned medium of OECs or MSCs differentiated into OECs or MSCs and this differentiation was also induced by cell-to-cell contact. When we cultured single CKL− cells on OEC- or MSC-conditioned medium, the cells differentiated morphologically and genetically into OEC- or MSC-like cells, respectively. Moreover, we confirmed that OECs or MSCs differentiated from CKL− cells had the ability to form capillary-like structures in Matrigel and differentiate into osteoblasts, chondrocytes, and adipocytes. Finally, using microarray analysis, we identified specific factors of OECs or MSCs that could potentially be involved in the differentiation fate of CKL− cells. Together, these results suggest that cord blood-derived CKL− cells possess at least bipotential differentiation capacity toward MSCs or OECs.

show abstract

Mesenchymal stem cells differentiated into chondrocyte—Like cells

Cited by 18 publications

References 34 publications

Differentiation of cardiomyocyte-like cells from human amniotic fluid mesenchymal stem cells by combined induction with human platelet lysate and 5-azacytidine

Differentiation of cardiomyocyte-like cells from human amniotic fluid mesenchymal stem cells by combined induction with human platelet lysate and 5-azacytidine

Human platelet lysate as an alternative to fetal bovine serum for culture and endothelial differentiation of human amniotic fluid mesenchymal stem cells

Human Cord Blood‐Derived CD133⁺/C‐Kit⁺/Lin⁻ Cells Have Bipotential Ability to Differentiate into Mesenchymal Stem Cells and Outgrowth Endothelial Cells

Contact Info

Product

Resources

About

Mesenchymal stem cells differentiated into chondrocyte—Like cells

Cited by 18 publications

References 34 publications

Differentiation of cardiomyocyte-like cells from human amniotic fluid mesenchymal stem cells by combined induction with human platelet lysate and 5-azacytidine

Differentiation of cardiomyocyte-like cells from human amniotic fluid mesenchymal stem cells by combined induction with human platelet lysate and 5-azacytidine

Human platelet lysate as an alternative to fetal bovine serum for culture and endothelial differentiation of human amniotic fluid mesenchymal stem cells

Human Cord Blood‐Derived CD133+/C‐Kit+/Lin− Cells Have Bipotential Ability to Differentiate into Mesenchymal Stem Cells and Outgrowth Endothelial Cells

Contact Info

Product

Resources

About

Human Cord Blood‐Derived CD133⁺/C‐Kit⁺/Lin⁻ Cells Have Bipotential Ability to Differentiate into Mesenchymal Stem Cells and Outgrowth Endothelial Cells